Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Marc Pritzker"'
Autor:
Thenappan Thenappan, Nadine Al-Naamani, Stefano Ghio, Hossein-Ardeschir Ghofrani, Paul M. Hassoun, Marc Pritzker, Adam Torbicki, Sylvia Nikkho, Dennis Busse, Ioana R. Preston
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Pulmonary arterial compliance is a measure of the pulsatile afterload of the right ventricle. Lower pulmonary arterial compliance is associated with reduced right ventricular function and worse prognosis in pulmonary hypertension. The effect of pulmo
Externí odkaz:
https://doaj.org/article/fb1233dee61f4e84935d564da314244d
Autor:
Kurt W. Prins, Rajat Kalra, Lauren Rose, Tufik R. Assad, Stephen L. Archer, Navkaranbir S. Bajaj, E. Kenneth Weir, Sasha Z. Prisco, Marc Pritzker, Pamela L. Lutsey, Evan L. Brittain, Thenappan Thenappan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 5 (2020)
Background Pulmonary arterial hypertension (PAH) is a lethal disease. In resource‐limited countries PAH outcomes are worse because therapy costs are prohibitive. To improve global outcomes, noninvasive and widely available biomarkers that identify
Externí odkaz:
https://doaj.org/article/8e82535fe49747acb0b42fcc5f11da4a
Autor:
ZEINA JEDEON, MARIA MASOTTI, JESSICA SCHULTZ, AMANDA R. VEST, TAMAS ALEXY, MARC PRITZKER, VALMIKI MAHARAJ, FORUM KAMDAR, RYAN KNOPPER, ANDREW SHAFFER, RANJIT JOHN, REBECCA COGSWELL
Publikováno v:
Journal of Cardiac Failure. 29:116-118
Autor:
Nathan Holthaus, Kurt W. Prins, Lauren Rose, Sasha Prisco, Marc Pritzker, Thenappan Thenappan
Publikováno v:
Pulmonary Circulation, Vol 9 (2019)
Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or soci
Externí odkaz:
https://doaj.org/article/276655fe2d6f4638b45d80071b4a87ba
Autor:
Kurt W. Prins, Lauren Rose, Stephen L. Archer, Marc Pritzker, E. Kenneth Weir, Matthew D. Olson, Thenappan Thenappan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 2 (2019)
Background Patients with pulmonary hypertension caused by chronic lung disease (Group 3 PH) have disproportionate right ventricle (RV) dysfunction, but the correlates and clinical implications of RV dysfunction in Group 3 PH are not well defined. Met
Externí odkaz:
https://doaj.org/article/3daca9a479614b4696f27fb4f68e40aa
Autor:
Kurt W. Prins, Thenappan Thenappan, E. Kenneth Weir, Rajat Kalra, Marc Pritzker, Stephen L. Archer
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 1 (2019)
Externí odkaz:
https://doaj.org/article/8b11c0786ab340b8b52f75f6b7c1c88d
Autor:
Jessica Schultz, Maria Masotti, Cindy M. Martin, Tamas Alexy, Thenappan Thenappan, Marc Pritzker, Forum Kamdar, Valmiki Maharaj, Amanda Vest, Rebecca Cogswell
Publikováno v:
Journal of Cardiac Failure. 28:S55-S56
Publikováno v:
Chest. 149(4)
Trastuzumab emtansine (T-DM1) is a Food and Drug Administration-approved novel agent for the treatment of HER-2 positive advanced breast cancer. We report a case of pulmonary arterial hypertension (PAH) that we attribute to the use of T-DM1. A 43-yea
Autor:
Hirad Yarmohammadi, Amy J Feng, Chadi M Alraies, Thenappan Thenappan, Monica Colvin, Ranjit John, Peter Eckman, Marc Pritzker, Sirtaz Adatya
Publikováno v:
Circulation. 130
Introduction: Unfractionated Heparin (UFH) has been the mainstay of therapy for bridging and treatment of suspected device thrombosis/hemolysis in Continuous Flow Left Ventricular Assist Device (CF-LVAD), however the optimal monitoring test has not b
Autor:
Marc Pritzker
Publikováno v:
Journal of cardiovascular translational research. 1(4)